Effect of β-amyloid on endothelial cells: Lack of direct toxicity, enhancement of MTT-induced cell death and intracellular accumulation

Neurochemistry International

Volumn 43, Issue 3, 2003, Pages 251-261

  Soriano, Francesc X ^a   Galbete, José Luis ^a   Forloni, Gianluigi ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; Endothelial cell lines; Toxicity; Vascular deposits; Amyloid

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATASE; AMYLOID BETA PROTEIN; BAFILOMYCIN A1; FORMAZAN; LACTATE DEHYDROGENASE; NEUTRAL RED;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL DEATH; CELL LINE; CELL ORGANELLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DEGRADATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; LYSOSOME; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TOXICITY;

AMYLOID BETA-PROTEIN; ANIMALS; BLOTTING, WESTERN; CELL DEATH; CELL LINE; ENDOTHELIUM; MICE; SUBCELLULAR FRACTIONS; TETRAZOLIUM SALTS; THIAZOLES;

MURINAE;

EID: 0037411846     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(03)00008-1     Document Type: Article

References (56)

1. Abe K., Saito H. Both oxidative stress-dependent and independent effects of amyloid β protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) reduction assay. Brain Res. 830:1999;146-154.
2. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
3. Berridge M.V., Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2, diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mithocondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303:1993;474-482.
4. Bhatia R., Lin H., Ratneshwar L. Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. FASEB J. 14:2000;1233-1242.
5. Blanc E.M., Toborek M., Mark R.J., Bernhard H., Mattson M.P. Amyloid-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68:1997;1870-1881.
6. Burdick D., Kosmoski J., Knauer M.F., Glabe C.G. Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide Aβ1-42 in differentiated PC12 cells. Brain Res. 746:1997;275-284.
7. Bussolino F., Rossi M., Sica A., Colotta F., Wang J.M., Bocchietto E.et al. Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines. J. Immunol. 147:1991;2122-2129.
8. Café C., Torri C., Bertorelli L., Angeretti N., Lucca E., Forloni G.et al. Oxidative stress after acute and chronic application of β amyloid fragment 25-35 in cortical cultures. Neurosci. Lett. 203:1996;1-5.
9. Chi X., Sutton E.T., Hellermann G., Price J.M. Potassium channel openers prevent β-amyloid toxicity in bovine vascular endothelial cells. Neurosci. Lett. 290:2000;9-12.
10. de la Torre J.C. Alzheimer disease as a vascular disorder. Stroke. 33:2002;1152-1162.
11. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 295:2002;2264-2267.
12. Drose S., Altendorf K. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol. 200:1997;1-8.
13. Farkas E., Luiten P.G.M. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64:2001;575-611.
14. Forloni G., Chiesa R., Smiroldo S., Salmona M., Tagliavini F., Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. NeuroReport. 4:1993;523-526.
15. Forloni G., Lucca E., Angeretti N., Della Torre P., Salmona M. Amidation of β-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J. Neurochem. 69:1997;2048-2054.
16. Garlanda C., Parravicini C., Sironi M., De Rossi M., Wainstok de Calmanovici R., Carozzi F.et al. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7291-7295.
17. Hertel C., Hauser N., Schubenel R., Seilhheimer B., Kemp J.A. β-Amyloid-induced cell toxicity: enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-dependent cell death. J. Neurochem. 67:1996;272-276.
18. Iadacola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E.et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:1999;157-161.
19. Inestrosa N., Deferrari G.V., Garrido J.L., Alvarez A., Olivares G.H., Barria M.I.et al. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem. Int. 41:2002;341-344.
20. Isobe I., Michikawa M., Yanigisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid β-protein and chloroquine in cultured rat astrocytes. Neurosci. Lett. 266:1999;129-132.
21. Kalaria R.N. Apolipoprotein E, arteriosclerosis and Alzheimer's disease. Lancet. 349:1997;1174-1175.
22. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging. 21:2000;321-330.
23. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13(Suppl. 2):2002;48-52.
24. Kane M.D., Schwarz R.D., St. Pierre L., Watson M.D., Emmerling M.R., Boxer P.A.et al. Inhibitors of V-Type ATPases, bafilomycin al and concanamycin a, protect against β-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2, dipheny1tetrazolinm bromide (MTT) reduction. J. Neurochem. 72:1999;1939-1947.
25. Kato M., Saito H., Abe K. Nanomolar amyloid beta protein-induced inhibition of cellular redox activity. J. Neurochem. 68:1997;1889-1895.
26. Knauer M.F., Soreghan B., Burdick D., Kosmoski J., Glabe C.G. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/β protein. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7437-7441.
27. Krogstad D.J., Schlesinger P.H. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. New Engl. J. Med. 317:1987;542-549.
28. Liu Y., Schubert D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J. Neurochem. 69:1997;2285-2293.
29. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 69:1997;581-593.
30. Lucca E., Angeretti N., Forloni G. Influence of cell culture conditions on the protective effect of antioxidants against β-amyloid: studies with lazaroids. Brain Res. 764:1997;293-298.
31. McGleenon B.M., Passmore A.P., McAuley D.F., Johnston G.D. No evidence of endothelial dysfunction in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11:2000;197-201.
32. Mosmann M.P. Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J. Immunol. Meth. 65:1983;55-63.
33. Munoz F.J., Opazo C., Gil-Gomez G., Tapia G., Fernandez V., Valverde M.A.et al. Vitamin E but not estradiol protects against vascular toxicity induced by beta-amyloid type and the Dutch amyloid variant. J. Neurosci. 22:2002;3081-3089.
34. Pakaski M., Balaspiri L., Checler F., Kasa P. Human amyloid-beta causes changes in the levels of endothelial protein kinase C and its alpha isoform in vitro. Neurochem. Int. 41:2002;409-414.
35. Paresce D.M., Chung H., Maxfield F.R. Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglial cells. J. Biol. Chem. 272:1997;29390-29397.
36. Paris D., Town T., Mori T., Parker T.A., Humphrey J., Mullan M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging. 21:2000;183-197.
37. Patel A.J., Gunasekera S., Jen A., Rohan de Silva H.A. β-Amyloid-mediated inhibition of redox activity (MTT reduction) is not an indicator of astroglial degeneration. NeuroReport. 7:1996;2026-2030.
38. Pittila T., Kim K.S., Mehta P.D., Frey H., Wisniewsky H.M. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer s disease, vascular dementia and controls. J. Neurol. Sci. 127:1994;90-95.
39. Preston J.E., Hipkiss A.R., Himsworth D.T.J., Romero I.A., Abbott J.N. Toxic effects of β-amyloid (25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and β-alanine. Neurosci. Lett. 242:1998;105-108.
40. Price J.M., Chi X., Hellermann G., Sutton P.T. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol. Res. 23:2001;506-512.
41. Rodriguez-Martin T., Calella A.M., Silva S., Munna E., Modena P., Chiesa R.et al. Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotypsin in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 11:2000;239-244.
42. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:1987;368-379.
43. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
44. Shearman M.S., Hawtin S.R., Tailor V.J. The intracellular component of cellular 3-(4, dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J. Neurochem. 65:1995;218-227.
45. 1-40 peptide from brain by low-density lipoprotein receptor-related protein-1 at the blood brain barrier. J. Clin. Invest. 106:2000;1489-1499.
46. Skovronsky D.M., Doms R.W., Lee V.M.Y. Detection of a novel intraneuronal pool of insoluble amyloid β protein that accumulates with time in culture. J. Cell Biol. 141:1998;1031-1039.
47. Smith M.A., Drew K.L., Nunomura A., Takeda A., Hirai K., Zhu X. Amyloid-beta tau alterations and mitochondrial dysfunction in Alzheimer disease the chickens or the eggs. Neurochem. Int. 40:2002;527-531.
48. Suo Z., Fang C., Crawford F., Mullan M. Superoxide free radical and intracellular calcium mediate Aβ1-42 induced endothelial toxicity. Brain Res. 762:1997;144-152.
49. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H. Intraneuronal Alzheimer Aβ42 accumulates in multivescicular bodies and is associated with synaptic pathology. J. Am. Pathol. 161:2002;1869-1879.
50. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171.
51. Vinters H.V., Secor D.L., Read S.L., Frazee J.G., Tomyiasu U., Stanley T.et al. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct. Pathol. 18:1994;333-348.
52. Winkler D.T., Bondolfi L., Herzing M.C., Jann L., Calhoun M., Wiederhold K.-H.et al. Spontaneous hemorrahagic stroke in mouse model of cerebral amyloid angiopathy. J. Neurosci. 21:2001;1619-1627.
53. Wirth K.J., Fink E., Rudolphi K., Heitsch H., Deutschländer N., Wiemer G. Amyloid β-(1-40) stimulates cyclic GMP production via release of kinins in primary cultured endothelial cells. Eur. J. Pharmacol. 382:2000;27-33.
54. Xu J., Chen S., Ku G., Abmed S.H., Chen H., Hsu C.Y. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J. Cereb. Blood Flow Metab. 21:2001;702-710.
55. Yankner B.S., Duffy L.K., Kirshner D.A. Neurotrophic and neurotoxic effects of β-amyloid protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.
56. Ziokovic B.V. Vascular disorder in Alzheimer's disease: role in the pathogenesis of dementia and therapeutic targets. Adv. Drug. Deliv. Rev. 54:2002;1553-1559.